Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 8, 2026

Shell fourth quarter 2025 update note

View original at finance.yahoo.com
Shell fourth quarter 2025 update note The following is an update to the fourth quarter 2025 outlook and gives an overview of our current expectations for the fourth quarter…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Marketing adjusted earnings are expected to be below Q4'24, reflecting a non-cash deferred tax adjustment in a joint venture

    80% confidence
  • The Chemicals sub-segment adjusted earnings are expected to be a significant loss, reflecting a non-cash deferred tax adjustment in a joint venture

    80% confidence
  • The Chemicals & Products segment adjusted earnings is expected to be below break-even in Q4'25

    80% confidence
  • Following swap of Canadian oil sands, there will be a reduction in Chemicals and Products Adjusted Earnings with a corresponding reduction in non-controlling interest for 50% at a Shell Group level

    80% confidence
  • Q4'25 Working Capital movements is expected to include the typical approximately $1.2 billion payment of German Mineral Oil Taxes

    80% confidence
  • No assurance is provided that future dividend payments will match or exceed previous dividend payments

    80% confidence
  • Trading & Optimisation is expected to be significantly lower than Q3'25 for Chemicals and Products

    80% confidence
  • The deferred tax impact on Joint Ventures and Associates in Marketing and Chemicals is expected to be approximately $0.3 billion split roughly equally

    80% confidence
  • Following the formation of the incorporated Adura JV (UK Upstream), future cash flows will be in the form of dividends, with timing determined by the JV

    80% confidence
  • The taxation charge across segments includes the annual non-cash reassessment of deferred tax assets

    80% confidence
  • CFFO excluding working capital is expected to include an approximately $1.5 billion outflow related to timing of payments of emissions certificates relating to the German BEHG

    80% confidence
  • Trading & Optimisation is expected to be in line with Q3'25 for Integrated Gas segment

    80% confidence

Data points we hold from this source

Shell plc · depreciation upstream2.4-3.0 billion_USD
Shell plc · adjusted earnings corporate-0.6 to -0.4 billion_USD
Shell plc · adjusted earnings renewables-0.2 to 0.2 billion_USD
Shell plc · cffo tax paid2.3-3.1 billion_USD
Shell plc · chemicals margin140 USD_per_tonne
Shell plc · chemicals utilisation75-79 percent
Shell plc · depreciation chemicals and products0.7-0.9 billion_USD
Shell plc · depreciation integrated gas1.4-1.8 billion_USD
Shell plc · depreciation marketing0.5-0.7 billion_USD
Shell plc · lng liquefaction volumes7.5-7.9 million_tonnes
Shell plc · oil sands production canada20 kboe_per_day
Shell plc · production integrated gas930-970 kboe_per_day
Shell plc · production upstream1840-1940 kboe_per_day
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com